TY - JOUR ID - 133479 TI - Assessing the frequency of t (12; 21) (p13; q22) in patients with acute lymphoblastic leukemia in northeastern of Iran JO - Health Biotechnology and Biopharma (HBB) JA - HBB LA - en SN - Y1 - 2018 PY - 2018 VL - 2 IS - 3 SP - 48 EP - 62 KW - Acute lymphoblastic leukemia lymphoma KW - TEL-AML1 KW - t (12 KW - 21) DO - 10.22034/HBB.2018.26 N2 - Studying the results of the prevalence of a particular genetic translocation of acute lymphoblastic leukemia (ALL) could predict the incidence rate of overall survival (OS) and event-free survival (EFS). 283 patients from northeastern of Iran with new diagnosis of ALL by bone marrow aspiration or peripheral blood sample were enrolled in the study. The expression of TEL-AML1 fusion were studied by TaqMan probe qualitative real time PCR compared with ABL reference gene. Then, the five-year survival rates were surveyed in the region of Khorasan Razavi and were analyzed by kaplan-meier test. Prevalence of t (12, 21) in patients with ALL was 14.4 %, survival rate was 75 %, and the average five-year survival rate for patients was 4.77 ± 39.76 months by the log-rank test. Prevalence of t (12, 21) in patients with ALL in the north east of Iran was lower than the world average. UR - https://www.healthbiotechpharm.org/article_133479.html L1 - https://www.healthbiotechpharm.org/article_133479_38971f1268566c0499e345e17b7ad18d.pdf ER -